Related Experiment Video
Updated: Jun 10, 2025
06:38
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
2.2K
Sterile Intraocular Inflammation Associated With Faricimab.
Mariano Cozzi1,2, Alexander Ziegler1, Katrin Fasler1
1Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
JAMA Ophthalmology
|October 10, 2024
Summary
Faricimab intravitreal injections may rarely cause severe intraocular inflammation, including retinal vasculitis. Continuous patient monitoring is crucial for early detection and management of potential adverse events.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacovigilance
Background:
- Randomized clinical trials assess drug safety and efficacy.
- Real-world adverse event data can generate hypotheses for rare safety issues.
Purpose of the Study:
- To analyze cases of intraocular inflammation following faricimab therapy.
- To investigate potential safety concerns in a clinical practice setting.
Main Methods:
- Observational case series review of patients receiving faricimab intravitreal injections.
- Analysis of ocular and systemic histories, multimodal imaging, and visual acuity.
- Evaluation of inflammation characteristics, intraocular pressure, and timing of events.
Main Results:
- Seven patients (12 eyes) developed noninfectious intraocular inflammation post-faricimab.
- Two cases presented with retinal vasculitis, one with severe vision loss.
- Inflammation occurred after a median of 3.5 injections, with diagnosis ~28 days after the last injection.
Conclusions:
- Faricimab therapy is associated with rare but potentially severe intraocular inflammation.
- Findings suggest the need for ongoing surveillance in patients receiving faricimab.
- Further research is warranted to understand causality and optimize patient management.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:27Open Angle Glaucoma: Treatment
401
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
401